Erik P. Castle, MD, highlights recent advances in surgery, individualized medicines, and immunotherapies for patients with renal cell carcinoma (RCC). He reviews updates in genetic sequencing and CAR-T cell therapy, as well as developing role of cancer-associated macrophage-like cells (CAMLs), in these patients.
Read More
Michael S. Cookson, MD, MMHC, suggests that the primary evidence does not provide convincing evidence in favor of 3 years of bacillus Calmette-Guérin (BCG) maintenance for non-muscle-invasive bladder cancer (NMIBC). He also notes that long-term BCG often leads to toxicities, contributing to low patient compliance.
Read More
E. David Crawford, MD, reviews the findings and recommendations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) I and II working groups. Phillip J. Koo, MD, then discusses the rationale for RADAR III and the expansion in recommendations from the first two iterations, focusing on updates regarding next generation imaging.
Read More
E. David Crawford, MD, reviews the historical developments in androgen deprivation therapy (ADT) for prostate cancer and the emergence of the non-metastatic castration-resistant, or M0, prostate cancer. He then describes future directions for treatment options for these patients with a focus on androgen pathway inhibitors.
Read More
Michael S. Cookson, MD, argues that neoadjuvant chemotherapy (NAC) is not appropriate or necessary for all patients with muscle invasive bladder cancer (MIBC) prior to cystectomy. Instead, physicians should use a selective approach to NAC to avoid unnecessary harms, toxicities, and delays in local therapy.
Read More